Related Experiment Video

Updated: Jun 5, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Structural basis for selective small molecule kinase inhibition of activated c-Met

Keith W Rickert1, Sangita B Patel, Timothy J Allison

  • 1Global Structural Biology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

The Journal of Biological Chemistry
|January 21, 2011
PubMed

Insights

Structural insights reveal how c-Met receptor tyrosine kinase activation occurs through autophosphorylation. This understanding aids in designing selective inhibitors, like MK-2461, for targeted cancer therapy.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Oncology

Background:

  • The c-Met receptor tyrosine kinase is crucial in cancer development.
  • c-Met activation by hepatocyte growth factor involves autophosphorylation.
  • Targeting c-Met is a strategy in cancer drug development.

Purpose of the Study:

  • To elucidate the structural basis of c-Met activation via autophosphorylation.
  • To understand the mechanism of selective small molecule inhibition of activated c-Met.
  • To provide a framework for structure-guided design of c-Met inhibitors.

Main Methods:

  • X-ray crystallography was used to determine the structure of the unbound, autophosphorylated c-Met kinase domain.
  • Crystal structure analysis of the complex between autophosphorylated c-Met and compound 1 (an MK-2461 analog).
  • Comparative structural analysis of phosphorylated and unphosphorylated c-Met states.

Main Results:

  • Autophosphorylation of c-Met at Tyr-1234/1235 induces activation loop disorder and rearrangements in helix αC and the G loop.
  • Compound 1 exhibits a 20-fold preference for the autophosphorylated c-Met kinase domain.
  • Complex formation reveals induced fit changes in the G loop and ordering of the activation loop, explaining selectivity.

Conclusions:

  • Structural plasticity of the kinase domain is key for specific ligand binding.
  • The findings facilitate the rational design of inhibitors targeting the activated state of c-Met.
  • This research supports the development of novel cancer therapeutics targeting c-Met.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...